Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tivozanib||Fotivda||AV-951|AV951|KIL-8951|KRN 951|KRN-951||VEGFR Inhibitor (Pan) 32||Fotivda (tivozanib) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). Fotivda(tivozanib) is FDA approved for use in adult patients with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||not applicable||Tivozanib||FDA approved||Actionable||In a Phase III trial (TIVO-3) that supported FDA approval, Fotivda (tivozanib) was better tolerated than Nexavar (sorafenib), and improved progression-free survival (5.6 vs 3.9 months, HR=0.73, p=0.016) in patients with metastatic renal cell carcinoma that had at least two previous systemic treatments (PMID: 31810797; NCT02627963).||detail... 31810797|
|Unknown unknown||renal cell carcinoma||not applicable||Tivozanib||Phase III||Actionable||In a Phase III trial, Fotivda (tivozanib) demonstrated improved progression free survival compared with Nexavar (sorafenib) as initial targeted therapy in patients with metastatic renal cell carcinoma (PMID: 24019545; NCT01030783).||24019545|
|NRAS mutant||acute myeloid leukemia||predicted - resistant||Tivozanib||Preclinical - Patient cell culture||Actionable||In a preclinical study, NRAS mutations correlated with resistance to Fotivda (tivozanib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).||30333627|
|Unknown unknown||Advanced Solid Tumor||not applicable||Tivozanib||Phase I||Actionable||In a Phase I clinical study, Fotivda (tivozanib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Clin Cancer Res, November 15, 2011 17; 7156).||detail...|
|Unknown unknown||fibrosarcoma||not applicable||Tivozanib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with Fotivda (tivozanib) resulted in partial inhibition of tumor growth and decreased tumor vasulature in a fibrosarcoma cell line xenograft model (PMID: 25995436).||25995436|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04645160||Phase Ib/II||Tivozanib||Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma||Not yet recruiting||USA||0|
|NCT01853644||Phase II||Tivozanib||Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Active, not recruiting||USA||0|
|NCT02627963||Phase III||Sorafenib Tivozanib||A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC||Active, not recruiting||USA | CAN||10|
|NCT01835223||Phase Ib/II||Tivozanib||Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery||Completed||USA||0|
|NCT01972516||Phase II||Tivozanib||Tivozanib As Maintenance Therapy In GYN||Terminated||USA||0|